inclusion criteria: * have voluntarily participated and be in regular follow-up monitoring by the covacmanaus study; * have completed the vaccination schedule with 2 doses of coronavac, as per the covacmanaus study protocol for at least 180 days (+/- 30 days); * demonstrate availability to be followed during the follow-up period defined in the study, through visits, telephone contacts or other digital means of communication; * accept to participate in this new study for 6 (six) months. exclusion criteria * confirmed diagnosis of covid-19 within the last 28 days (antigen test or rt-pcr). in this situation, vaccination can be postponed until the participant completes 30 days; * report of fever within 72 hours prior to vaccination (inclusion can be postponed until the participant completes 72 hours without fever and covid-19 is discarded); * having received live attenuated virus vaccine in the last 28 days or inactivated vaccine in the last 14 days prior to inclusion in the study; * any other condition that, in the opinion of the principal investigator or its medical representative, could jeopardize the safety or rights of a potential participant or prevent them from complying with this protocol; * pregnancy or lactation.

inclusion criteria: * have voluntarily participated and be in regular follow-up monitoring by the covacmanaus study; * have completed the vaccination schedule with 2 doses of coronavac, as per the covacmanaus study protocol for at least 180 days (+/- 30 days); * demonstrate availability to be followed during the follow-up period defined in the study, through visits, telephone contacts or other digital means of communication; * accept to participate in this new study for 6 (six) months. exclusion criteria * confirmed diagnosis of covid-19 within the last 28 days (antigen test or rt-pcr). in this situation, vaccination can be postponed until the participant completes 30 days; * report of fever within 72 hours prior to vaccination (inclusion can be postponed until the participant completes 72 hours without fever and covid-19 is discarded); * having received live attenuated virus vaccine in the last 28 days or inactivated vaccine in the last 14 days prior to inclusion in the study; * any other condition that, in the opinion of the principal investigator or its medical representative, could jeopardize the safety or rights of a potential participant or prevent them from complying with this protocol; * pregnancy or lactation.

inclusion criteria: have voluntarily participated and be in regular follow-up monitoring by the covacmanaus study; have completed the vaccination schedule with 2 doses of coronavac, as per the covacmanaus study protocol for at least 180 days (+/- 30 days); demonstrate availability to be followed during the follow-up period defined in the study, through visits, telephone contacts or other digital means of communication; accept to participate in this new study for 6 (six) months. exclusion criteria confirmed diagnosis of covid-19 within the last 28 days (antigen test or rt-pcr). in this situation, vaccination can be postponed until the participant completes 30 days; report of fever within 72 hours prior to vaccination (inclusion can be postponed until the participant completes 72 hours without fever and covid-19 is discarded); having received live attenuated virus vaccine in the last 28 days or inactivated vaccine in the last 14 days prior to inclusion in the study; any other condition that, in the opinion of the principal investigator or its medical representative, could jeopardize the safety or rights of a potential participant or prevent them from complying with this protocol; pregnancy or lactation.

inclusion criteria: have voluntarily participated and be in regular follow-up monitoring by the covacmanaus study; have completed the vaccination schedule with 2 doses of coronavac, as per the covacmanaus study protocol for at least 180 days (+/- 30 days); demonstrate availability to be followed during the follow-up period defined in the study, through visits, telephone contacts or other digital means of communication; accept to participate in this new study for 6 (six) months. exclusion criteria confirmed diagnosis of covid-19 within the last 28 days (antigen test or rt-pcr). in this situation, vaccination can be postponed until the participant completes 30 days; report of fever within 72 hours prior to vaccination (inclusion can be postponed until the participant completes 72 hours without fever and covid-19 is discarded); having received live attenuated virus vaccine in the last 28 days or inactivated vaccine in the last 14 days prior to inclusion in the study; any other condition that, in the opinion of the principal investigator or its medical representative, could jeopardize the safety or rights of a potential participant or prevent them from complying with this protocol; pregnancy or lactation.